Issue link: https://www.e-digitaleditions.com/i/1276475
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 20 August 2020 Inhalation Issue Focus This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. particle characterization Semi- and fully automated particle size determination Astech provides semi- and fully automated parti- cle size determination (PSD) testing instruments that enable traceable test data at each step. Astech has established automated inhaler testing solutions for Next Generation (NGI) and Andersen cascade impactors. Our automated inhaler testing equipment comes with Relovex ® , our easy to use, intuitive 21 CFR Part 11 and data integrity compliant software for fully traceable test results. Astech offers f lexible custom automation solutions to automate your inhaled drug delivery testing process from start to finish. Astech Projects UK: +44 1928 571797 www.astechprojects.co.uk Ensuring proper particle characterization With ongoing scrutiny of drug compliance, consis- tency and patient safety, it is more important than ever to ensure your test systems operate within original specifications. Without proper cleaning, calibration and mensuration, it cannot be assumed that your par- ticle characterization collection is reliable. MSP offers a variety of service options within USP <1058> guide- lines to ensure your analytical instruments perform within given specifications—avoiding bridging stud- ies and saving you money and time. MSP, a division of TSI US: +1 651 287-8100 www.tsi.com Contract particle characterization services Proveris Laboratories offers OINDP expertise to pharmaceutical developers, including contract ser- vices employing new innovative in vitro techniques outlined by the US FDA. ese include measuring spray velocity, evaporation rate and quantif ying deposition of inhaled drug products using human- realistic models. For generic drug developers, these tests can serve as an alternative in vitro approach to evaluate bioequivalence between test and reference products. Innovator drug developers can utilize the data generated to help guide key early decisions regarding device selection, formulation development and in vitro/in vivo correlations (IVIVC). Proveris Scientific Corporation US: +1 508 460-8822 www.proveris.com